Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer

Alisa J. Prager, Cynthia R. Peng, Elena Lita, Debbie Mcnally, Aradhana Kaushal, Mary Sproull, Kathryn Compton, William L. Dahut, William D. Figg, Deborah Citrin, Kevin A. Camphausen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Aim: Serum PSA screening for prostate cancer (PCa) is controversial. Here, we identify three urinary biomarkers - aHGF, IGFBP3 and OPN - for PCa screening and prognostication. Methods: Urinary aHGF, OPN and IGFBP3 from healthy men (n = 19) and men with localized (n = 65) and metastatic (n = 36) PCa were quantified via ELISA. Mann-Whitney nonparametric t-test and the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) analyses were used to analyze associations. Results: Mean aHGF and IGFBP3 levels were significantly elevated in PCa patients versus controls (p = 0.0006 and p = 0.0012, respectively), and the area under the curve of the receiver operating characteristic curve (indicator of diagnostic accuracy) for aHGF and IGFBP3 was 0.75 and 0.74, respectively. OPN levels were significantly higher in metastatic groups (p = 0.0060) versus localized and controls (area under the curve = 0.68). Conclusion: Urinary aHGF and IGFBP3 exhibit the capacity for diagnostic discrimination for PCa, whereas OPN may indicate presence of metastatic disease.

Original languageEnglish
Pages (from-to)831-841
Number of pages11
JournalBiomarkers in Medicine
Issue number6
StatePublished - Dec 2013
Externally publishedYes


  • HGH
  • OPN
  • biomarker
  • prostate cancer
  • urine


Dive into the research topics of 'Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer'. Together they form a unique fingerprint.

Cite this